NDAORALFOR SUSPENSION
Approved
Mar 1982
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SPECTROBID (bacampicillin hydrochloride) is an oral beta-lactam antibiotic prodrug of ampicillin, approved in 1982 for bacterial infections. It is converted to ampicillin in vivo and is administered as a suspension formulation. The drug treats susceptible gram-positive and gram-negative bacterial infections via inhibition of bacterial cell wall synthesis.
LOE Approaching
With LOE approaching and 30% competitive pressure, this product faces significant generic erosion; commercial teams should expect consolidation and focus on cost-containment strategies.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SPECTROBID offers limited career growth potential given its LOE-approaching status and declining market relevance; roles focus on legacy product management and generic defense strategies. Career progression is best pursued by transitioning to Pfizer's growth-stage pipeline assets or specialty/hospital antibiotics.
Product ManagerField Sales Representative
Worked on SPECTROBID at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.